NCT04723901

Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia

Clinical Trial of CD19/CD22 Dual Target CAR-T Cells in the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Shenzhen University General Hospital · Academic / Other
• Sex: All
• Age: 14 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Prospectively evaluate the safety and effectiveness of CD19/CD22 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

Detailed description

Prospectively evaluate the safety and effectiveness of CD19/CD22 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Strictly follow the inclusion criteria to screen eligible subjects for inclusion in clinical trials. The selected patients received CD19/CD22 dual-target CAR-T cell therapy. After the treatment is over, follow-up regularly to determine the survival status and follow-up treatment.

Conditions

• Dual-target CAR-T Cells
• B ALL
• Relapse
• Refractory B Acute Lymphoblastic Leukemia

Interventions

Type	Name	Description
BIOLOGICAL	Dual target CAR-T cell therapy	CD19/CD22 dual target CAR-T cell therapy

Timeline

• Start date: 2020-10-20
• Primary completion: 2022-12-31
• Completion: 2022-12-31
• First posted: 2021-01-26
• Last updated: 2021-01-26

Locations

1 site across 1 country: China